The use of TRPV1 antagonists and the knockdown of TRPV1 protein resulted in reduced sensitivity to nociception in preclinical pain models, for instance in neuropathic, osteoarthritic, postoperative pain, and cancer pain, with special regard to CIBP, with variability in their analgesic effects, possibly due to differences in their pharmacological properties. Here, TRPV1 is linked to cancer.